Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pressure BioSciences, Inc.    PBIO

SummaryNewsCalendarCompanyFinancialsConsensus 
News SummaryMost relevantAll newsSector news 

Pressure Biosciences : Pressure BioSciences, Inc. Upgraded by EdgeWater Research Partners LLC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/27/2006 | 04:48pm CET

Pressure BioSciences, Inc. (NASDAQ: PBIO) today announced that in an update to an initial research report on the Company, EdgeWater Research Partners LLC (?EdgeWater?) has upgraded PBI's rating from a 4 to a 6 and re-established a 12-18 month price target. Of the 20 companies currently covered by EdgeWater, only one has a rating greater than 6.

Copies of the updated and initial research reports on PBI can be obtained free of charge by contacting Mr. David Lavigne at EdgeWater (www.edgewaterresearch.com or 303-593-2877).

Analyst Coverage Disclaimer

Pressure BioSciences is announcing the availability of EdgeWater's updated research report solely for convenience. Any opinions, estimates, or forecasts regarding Pressure BioSciences' historical or predicted performance or operations, including predictions of stock price, made by EdgeWater are theirs alone and do not represent opinions, judgments, estimates, or forecasts of Pressure BioSciences or its management. Pressure BioSciences does not endorse, adopt, or concur with information, conclusions, or recommendations in either EdgeWater's initial or updated research reports on the Company. Pressure BioSciences subscribes for EdgeWater's newsletter and research information, and has purchased EdgeWater's research reports. For the past two years, Pressure BioSciences has paid a fee of $8000 to attend and present at EdgeWater's fall Micro/Small Cap Conference for Investment Professionals.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-QSB for the quarter ended September 30, 2006; in the Company's Annual Report on Form 10-KSB, as amended, for the year ended December 31, 2005; and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com


© Business Wire 2006
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PRESSURE BIOSCIENCES, INC.
11/21 PRESSURE BIOSCIENCES : PBIO) Achieves Record Revenue on Road to Profitability --..
11/21 PRESSURE BIOSCIENCES INC : WallStreet Research Announces Availability of Updated..
11/16 PRESSURE BIOSCIENCES, INC. : Reports Third Quarter 2016 Financial Results and Pr..
11/15 PRESSURE BIOSCIENCES : Management's Discussion and Analysis of Financial Conditi..
11/14 PRESSURE BIOSCIENCES : Announces Initial Close of $610,000 in $2.5 Million Priva..
11/11 PRESSURE BIOSCIENCES, INC. : to Discuss Third Quarter 2016 Financial Results and..
11/04 PRESSURE BIOSCIENCES, INC. (OTCQB : PBIO) Files An 8-K Closes $2,000,000 Line-of..
11/04 PRESSURE BIOSCIENCES : PBIO) Secures Funding Allowing for Accelerated Corporate ..
11/03 PRESSURE BIOSCIENCES INC : Entry into a Material Definitive Agreement, Unregiste..
11/03 PRESSURE BIOSCIENCES, INC. : Closes $2,000,000 Line-of-Credit
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
11/22DJMEDTRONIC : Cuts Guidance on Sluggish Revenue
11/22DJMEDTRONIC : Cuts Guidance on Sluggish Revenue -- 2nd Update
11/22DJMEDTRONIC : Cuts Guidance on Sluggish Revenue
11/15 EXCLUSIVE : EU regulators seen clearing $25 billion Abbott, St Jude deal
11/15 Exclusive - EU regulators seen clearing $25 billion Abbott, St Jude deal
More sector news : Medical Equipment, Supplies & Distribution - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
Consensus details
Managers
NameTitle
Richard T. Schumacher President, CEO, CFO, Secretary & Treasurer
Jeffrey N. Peterson Chairman
Edmund Y. Ting Senior Vice President-Engineering
Vito J. Mangiardi Independent Class II Director
Kevin A. Pollack Independent Class II Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PRESSURE BIOSCIENCES, ..9
MEDTRONIC PLC-6.38%99 513
BAXTER INTERNATIONAL I..14.36%23 938
ZIMMER BIOMET HOLDINGS..-2.33%20 070
C R BARD INC10.83%15 438
HOYA CORPORATION-9.17%15 327
More Results